Avextra's Innovative Approach to Patient-Centric Therapy
With evidence-based clinical development and new pharmaceutical formulations, Avextra aims to enhance patient experience and adherence.
In the ever-evolving realm of medical therapies, the question arises: How can treatments involving Cannabis-based medicines (CbM) be both effective and user-friendly? Traditionally, oily solutions have dominated the market, particularly for pain management. However, despite their proven effectiveness, these solutions often lack convenience. Recognizing this challenge, Avextra, a pioneering German biotech firm, is making significant strides with the launch of a new line of products that includes capsules, a more standardized and potentially easier-to-use dosage form.
The Role of Avextra Capsules in Patient Care
Crafted with care, these capsules are filled with granulates containing Avextra's proprietary Cannabis extract, formulated as Avextra 10:10 (THC/CBD). Their introduction follows a comprehensive study designed to evaluate patient satisfaction across various oral cannabis forms. This extensive, prospective multicentric SATURN study included almost 400 participants across 24 centers, aiming to improve quality of life (QoL) in pain patients through personalized treatment approaches.
Impressive Outcomes from the SATURN Study
The SATURN study yielded remarkable findings after participants had undergone three months of treatment. Both the oily Cannabis extract Avextra 10:10 and the new Cannabis extract capsules showed superior results in alleviating symptoms while enhancing quality of life for users. Notably, treatment with the Avextra capsules (available in 2.5 mg and 5 mg THC/CBD ratios) displayed significantly better outcomes compared to the existing extracts. Patients reported a marked improvement in conditions like sleep disturbances, chronic pain from various ailments, and overall health perceptions.
Key Insights from Patient-Reported Experiences
The results of the SATURN study are compelling:
- Efficacy: The Avextra capsules exhibited substantially higher responder rates for quality of life improvements and symptom relief compared to traditional cannabis extracts after six months of treatment.
- Medication Reduction: A notable 37% of patients reported a decrease in their previous medications, including analgesics and antidepressants, as a direct result of using Avextra’s products.
- High Patient Satisfaction: Satisfaction levels soared, with 68% of users expressing contentment with the oily extract and an impressive 90% satisfied with the new capsule form.
- Therapy Continuation: Remarkably, 85% of patients indicated they would opt for Avextra’s cannabis medications again, showcasing the strong belief in the product's effectiveness.
Commitment to Advancing Cannabis Medicine
The findings from SATURN are a testament to the importance of developing patient-oriented, standardized oral medications that enhance usability and maintain therapeutic efficacy. Avextra’s introduction of the capsule line signifies an essential step toward offering accessible and effective cannabinoid-based treatment options.
Expert Commentary on the Research Findings
Reflecting on the SATURN study, Prof. Dr. med. Justus Benrath, the principal investigator, emphasized the importance of including a diverse array of patients, from those new to cannabis therapies to experienced users. This approach allowed for a comprehensive evaluation of how these treatments impact patient satisfaction, quality of life, and overall tolerability.
Ongoing Commitment to Research and Development
Avextra remains steadfast in its dedication to further research, aiming to explore the long-term benefits of cannabinoid therapies in areas where patient needs are significant and unmet. Dr. Bernhard Babel, CEO of Avextra, stated that patient-related outcomes and individual treatment goals are integral to the development of future studies, allowing for deeper insights into effective treatment solutions for severely ill patients. This reinforces the recognition that cannabis medicines are generally well tolerated and contribute positively to pain management.
About Avextra AG
Avextra is a German biotechnology company committed to pioneering cannabis-based prescription medicines. The firm is heavily invested in innovative research, currently conducting multiple groundbreaking studies aimed at regulatory approval to enhance the treatment landscape for patients requiring pain management and palliative care. The company's mission is to develop effective strategies that improve the reimbursement process for cannabinoid therapies.
For further inquiries, please reach out to Avextra’s dedicated media contact:
Avextra Media Enquiries:
Email: press@avextra.com | Phone: +49 30 408174037
Frequently Asked Questions
What type of products does Avextra offer?
Avextra specializes in cannabis-based prescription medications, focusing on standardized oral dosage forms like capsules.
How many patients were involved in the SATURN study?
Nearly 400 patients participated in the SATURN study, which evaluated various oral cannabis products.
What improvements did patients report after using Avextra capsules?
Patients experienced significant improvements in symptom relief and overall quality of life.
What percentage of patients wanted to continue using Avextra products?
85% of patients expressed their willingness to use Avextra cannabis medications again.
What is Avextra's main goal in conduct research?
Avextra aims to enhance the reimbursement process for cannabinoid treatments, ensuring better access for patients in pain management and palliative care.
